American Society for Pharmacology & Experimental Therapeutics (ASPET) has signed a license for closed-access peer-reviewed content to create a community for scientists, publishers and suppliers with BenchSci.
August 1, 2017, Toronto CANADA, and Bethesda MD, USA — BenchSci, an AI discoverability platform that decodes scientific papers, and extracts usage data for biological compounds and the related figures to help scientists design better experiments, is pleased to announce that it has successfully completed a license agreement with ASPET to include its four journals on the BenchSci platform to increase discoverability of relevant scientific compounds discussed within ASPET-published articles.
Founded in 2014, BenchSci has spent the last three years applying and refining its proprietary machine learning algorithm, decoding millions of Open Access (OA) scientific papers and over 3.7 million antibody products. BenchSci has further developed its platform with the assistance of numerous world-class academic institutions such as Georgetown University, University of Toronto, The University of Texas MD Anderson Cancer Center, and Baylor College of Medicine. BenchSci is now being used at these institutions and by many major pharmaceutical and biotechnology companies across North America.
However, OA papers only represent a subset of all scientific literature. Scientists generally use resources like Google or PubMed, and are missing out on tools and other resources that publishers might offer. BenchSci therefore has initiated talks with publishers to make their content discoverable through BenchSci, without a loss of readership or traffic to their sites. BenchSci’s machine learning technology pinpoints the exact information scientists are looking for within the paper, and displays the relevant figures for them to identify the appropriate articles to read. The figures act as a window into the published article, giving scientists more confidence that the information relevant to their search parameters is located within the paper. Researchers are then redirected back to the publisher website to access the full text.
“’Publish or perish’ is a driving force for scientists, but funding resources are limited. Scientists need to find the right products for their research, and fast. BenchSci prevents a waste of time and resources by bringing scientists to the relevant information they need in a fraction of the time,” said Liran Belenzon, CEO of BenchSci. “The partnership between BenchSci and ASPET allows us to continue our mission to accelerate the pace of scientific research by generating a more comprehensive database and allowing scientist to harness the power of the BenchSci platform.”
Rich Dodenhoff, Journals Director at ASPET said, “We are very pleased to have ASPET’s journals indexed by BenchSci so that researchers can quickly and efficiently find the content they need. BenchSci is a powerful tool that will save hours of tedious work. BenchSci’s AI capabilities enable researchers to expeditiously find the content in ASPET’s journals that meets their needs. This is an important service to anyone working in pharmacology and related fields.”
About BenchSci: As a team of former bench scientists, we experienced the challenges of finding commercial antibodies first-hand. We used to spend hours, and sometimes even days, searching for antibody usage data in the literature. Those days are now over! In the past 2 years, we have developed a machine learning software that can find and extract antibody usage data in the form of published figures. We used our software to decode millions of papers, and then took all the data, indexed it, and made it easily discoverable for scientists.
Our goal is to help scientists find antibodies that have been proven to work by the scientific community, and therefore achieve scientific discoveries faster.
About ASPET and ASPET Journals: The American Society for Pharmacology and Experimental Therapeutics is a 5,000 member scientific society whose members conduct basic and clinical pharmacological research and work for academia, government, large pharmaceutical companies, small biotech companies, and even non-profit organizations.
ASPET members work in a variety of different fields and include neuroscientists, toxicologists, chemical biologists, pharmacists, cardiovascular scientists, and many more.
Though very diverse, our members have a common bond through their membership in ASPET. Our members research efforts help develop new medicines and therapeutic agents to fight existing and emerging diseases.